TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06271473

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vitrectomy + ILM peeling +/- planned foveal detachment via subretinal injection of ringer's solution.
Description: vitrectomy + ILM peeling +/- planned foveal detachment via subretinal injection of ringer's solution.
Study: NCT06293196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure
Description: Massage acupoints and non-acupoint areas around the eyes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure
Description: Massage acupoints and non-acupoint areas around the eyes.
Study: NCT05803603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stipend and Social Work Supports
Description: Same as arm description
Study: NCT06412016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Nutritional Counseling + Urban Gardening
Description: Peer nutritional counseling and urban gardens
Study: NCT06504056

Intervention type: BIOLOGICAL
Intervention: Diagnosis of NVM
Description: The term 'left ventricular non-compaction' (LVNC) has been used to describe a ventricular phenotype characterized by prominent LV trabeculae and deep intertrabecular recesses. The myocardial wall is often thickened with a thin,compacted epicardial layer and a thickened myocardial layer. In some patients, this abnormal trabecular architecture is associated with LV dilatation and systolic dysfunction. Left ventricular non-compaction is frequently a familial trait and is associated with variants in a range of genes, including those encoding proteins of the sarcomere, Z-disc, cytoskeleton, and nuclear envelope.

Intervention type: BIOLOGICAL
Intervention: Diagnosis of NVM
Description: The term 'left ventricular non-compaction' (LVNC) has been used to describe a ventricular phenotype characterized by prominent LV trabeculae and deep intertrabecular recesses. The myocardial wall is often thickened with a thin,compacted epicardial layer and a thickened myocardial layer. In some patients, this abnormal trabecular architecture is associated with LV dilatation and systolic dysfunction. Left ventricular non-compaction is frequently a familial trait and is associated with variants in a range of genes, including those encoding proteins of the sarcomere, Z-disc, cytoskeleton, and nuclear envelope.

Intervention type: BIOLOGICAL
Intervention: Diagnosis of NVM
Description: The term 'left ventricular non-compaction' (LVNC) has been used to describe a ventricular phenotype characterized by prominent LV trabeculae and deep intertrabecular recesses. The myocardial wall is often thickened with a thin,compacted epicardial layer and a thickened myocardial layer. In some patients, this abnormal trabecular architecture is associated with LV dilatation and systolic dysfunction. Left ventricular non-compaction is frequently a familial trait and is associated with variants in a range of genes, including those encoding proteins of the sarcomere, Z-disc, cytoskeleton, and nuclear envelope.
Study: NCT05118412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lucerne protein concentrate shake
Description: At three out of five test days: Lucerne protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey protein concentrate shake
Description: At two out of five test days: Whey protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.
Study: NCT05135364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Each infusion is 30 min (not less than 20 min, not more than 60 min), once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC
Description: A chemotherapy regimen perfused through the tumor supplying artery, d1-2 administration, perfused every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI
Description: Lenvatinib or Regorafenib
Study: NCT05741021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F520
Description: F520 is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: A chemotherapy medication used to treat a number of types of cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: A chemotherapy medication used to treat a number of types of cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: A chemotherapy medication for the treatment of pleural mesothelioma and non-small cell lung cancer (NSCLC).
Study: NCT06545864

Intervention type: DRUG
Intervention: Streptokinase Injection
Description: 250000 IU as a loading dose over 30 min. Followed by 100000 IU/hour over 12:24hours or accelerated regimen 1.5 million IU over 2 hours

Intervention type: DEVICE
Intervention: Penumbra System
Description: which comprised of several devices:~* RED Reperfusion Catheters~* Penumbra JET Reperfusion Catheters~* ACE Reperfusion Catheters~* MAX Reperfusion Catheters~* 3D Revascularization Device~* Penumbra ENGINE Aspiration Source~* Penumbra ENGINE Canister~* Aspiration Tubing
Study: NCT05327738

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Yttrium Y 90 Glass Microspheres
Description: Given intra-arterially
Study: NCT06551558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: global warming
Description: A systematic pre- and post-operative warming associated with the optimization of per-operative warming.

Intervention type: OTHER
Group type: OTHER
Intervention: per operative warming
Description: per-operative warming only thanks to the Optimized Forced air blanket with a prewarming of 10 minutes performed in the operating room.
Study: NCT05115253

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HAPA behavioural counselling + SMS text message boosters
Description: Behavioural counseling grounded in the Health Action Process Approach (HAPA; i.e., action planning and coping planning) paired with daily personalized HAPA guided SMS text message boosters to reduce consecutive workplace sedentary behaviour.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JITAI
Description: EMA monitoring mobile phone application that uses a phone's on-board accelerometer to monitor a participant's sedentary behaviour and deliver a push notification once a set condition has been met. This intervention will be utilized to reduce consecutive workplace sedentary behaviour.
Study: NCT04806451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crinecerfont
Description: CRF1-receptor antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Crinecerfont
Description: CRF1-receptor antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active dosage form
Study: NCT06121674

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shaeer-II
Description: SHAEER-I targets ligation of the internal pudendal vein at the point where the vein exits Alcock's canal, and courses lateral to the ischial tuberosity.~Patient is oriented in the lithotomy position. The ischial tuberosity is marked. An incision is cut medial to the ischial tuberosity. Subcutaneous fat is dissected down to the neurovascular bundle harboring the internal pudendal vein. The vein is then ligated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PPI
Description: Penile Prosthesis Implantation will be performed
Study: NCT06261814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur Hexafluoride Lipid Microspheres
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Ultrasound
Description: Undergo CEUS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial Chemoembolization
Description: Undergo TACE

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Ancillary studies
Study: NCT05951582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric Exercises
Description: The group will receive plyometric exercises in a controlled environment. Following Plyometrics were performed.~1. Horizontal jumps over hurdle.~2. Standing long jump~3. Front cone hops~4. Forward-backward run~5. Double leg horizontal jump~6. Lateral jump over hurdle~7. Side to side sprint~8. Jumps over low hurdles~9. Split squat jump~10. Cone hops with change of sprint direction~11. Lateral jump over hurdle~12. Side to side slide and hops.~13. Lateral and horizontal jump~14. Cone hops with 180o turn~15. Vertical, Lateral, and horizontal jump~16. Lateral cone jump~17. Single leg lateral jump~18. Diagonal Jumps.~19. Standing long jump with diagonal sprint.~20. Single leg vertical jump~21. Cone hop with 1800 turn~22. Skipping over cone

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Exercises
Description: The group will receive conventional exercises in a controlled environment. Following conventional exercises were performed.~1. Single Leg Squat/ Lunges~2. Modified Box Step Ups~3. Press Ups~4. Box Jumps~5. Shoulder Press~6. Standing Band Row~7. Band Butterfly Pills
Study: NCT05723146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spatial cognition assessment
Description: The intervention will be composed of tasks assessing spatial cognition in a real environment (cancellation task, line bisection and baking tray task) and in a virtual environment (cancellation task, line bisection, baking tray task and localization tasks).The Catherine Bergego Scale (questionnaire) will also be used.
Study: NCT05432544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1918
Description: Ascending dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR-1918 placebo
Description: Ascending dose
Study: NCT05394298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short-treatment of any active antibiotic regimen 7 days of any active antibiotic treatment for uncomplicated enterococcal bacteremia.
Description: Any active antibiotic with treatment with proven in vitro activity from a pre-stablished list of antibiotics included

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long-treatment of any active antibiotic regimen 14 days of any active antibiotic treatment for uncomplicated enterococcal bacteremia.
Description: Any active antibiotic with treatment with proven in vitro activity a pre-stablished list of antibiotics included
Study: NCT05990803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: BL-B01D1 was administered by intravenous infusion on D1 and D8 in a 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B003
Description: SI-B003 was administered by intravenous infusion every 3 weeks (Q3W).
Study: NCT06275126

Intervention type: OTHER
Group type: OTHER
Intervention: CONSYDER decision aid
Description: Web-based breast cancer surgery decision aid
Study: NCT05097911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTL-CEBPA
Description: The starting dose will be at dose level 1. For cycle 1 only, there will be a lead-in period whereby patients will receive one dose of MTL-CEBPA, 7 days prior to cycle 1 day 1. MTL-CEBPA is then administered on Day 1 and 8 of each cycle, atezolizumab is administered on Day 1 of each cycle and bevacizumab is administered on Day 1 of each cycle. One cycle of treatment consists of 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: The starting dose will be at dose level 1. For cycle 1 only, there will be a lead-in period whereby patients will receive one dose of MTL-CEBPA, 7 days prior to cycle 1 day 1. MTL-CEBPA is then administered on Day 1 and 8 of each cycle, atezolizumab is administered on Day 1 of each cycle and bevacizumab is administered on Day 1 of each cycle. One cycle of treatment consists of 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: The starting dose will be at dose level 1. For cycle 1 only, there will be a lead-in period whereby patients will receive one dose of MTL-CEBPA, 7 days prior to cycle 1 day 1. MTL-CEBPA is then administered on Day 1 and 8 of each cycle, atezolizumab is administered on Day 1 of each cycle and bevacizumab is administered on Day 1 of each cycle. One cycle of treatment consists of 21 days.
Study: NCT04696549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual visual art experience guided by Visual Thinking Strategies
Description: All study dyads (where study dyad consists of a participant with dementia and his/her care-partner) will participate in 3 scheduled virtual visual art sessions via Zoom. Each session will last about an hour and will include a guided discussion of pre-selected visual art using the Visual Thinking Strategies approach. It is anticipated that two pieces of art will be shown during each art session. The three sessions will be scheduled one month apart.
Study: NCT04141696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Given intravenously over 40 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam (placebo)
Description: Given intravenously over 40 minutes
Study: NCT05587881

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine(donor)
Description: Donor received COVID-19 vaccine before stem cells collection.

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine(donor)
Description: Donor received COVID-19 vaccine before stem cells collection.

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine(patient)
Description: Patient received COVID-19 vaccine before allo-HSCT.

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine(patient)
Description: Patient received COVID-19 vaccine before allo-HSCT.
Study: NCT04697914

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Plantar pressures will be measured in 7 zones using the Footscan® platform following the two-step method. Three plantar pressures measurements were made for each foot.
Description: to protect the metatarsus and prevent the appearance of foot pain.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Plantar pressures will be measured in 7 zones using the Footscan® platform following the two-step method. Three plantar pressures measurements were made for each foot.
Description: to protect the metatarsus and prevent the appearance of foot pain.
Study: NCT04381130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EF-009
Description: Subjects who meet the eligibility criteria will have completed following evaluations and assessments before receiving treatment: a) review of medical and medication history; b) physical examination, vital signs and documentation of ECOG; c) ECG; d) routine serum biochemical, hematologic, urine pregnancy (if applicable) and urine laboratory assessments; and e) evaluation of European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 score.~On Day 0, subjects will undergo EF-009 wafer implantation via laparoscopy
Study: NCT05180253

Intervention type: DIAGNOSTIC_TEST
Intervention: Esophageal studies
Description: Healthy subjects will undergo esophageal and blood testing.
Study: NCT05584345

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: Cold pack, ultrasound, TENS, finger ladder, Codman, shoulder wheel, and Wand exercises, as well as stretching and capsule exercises, will be used in addition to conventional physiotherapy. Exercises with a wand will be performed 10 times in each direction. There will be 30 repetitions in each direction of the Codman exercises. 5 days a week, for a total of 30 sessions, the afflicted shoulder will get 6 minutes of daily US treatment, with complete contact to the shoulder area and at a right angle. All patients will receive manual stretching in the shoulder flexion, abduction, extension, external rotation, and internal rotation directions. The physiotherapist will perform these stretches 5 times in each direction, pausing for 20 seconds at the conclusion of each repeat. TENS will be applied for 20 minutes. In addition, a 15-minute cold pack application will be made to the shoulder region. The application of theraband strengthening exercises will depend on the patients' state.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory Exercises
Description: Diaphragmatic breathing and thoracic expansion breathing exercises will be applied 5 days a week.
Study: NCT05170607

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomic analysis by antibody microarrays
Description: Proteomic analysis by antibody microarrays can be used to identify novel biomarkers and to investigate various signaling pathways including protein phosphorylation and protein-protein interactions. Microchips are manufactured as a matrix of a number of immobilized antibodies covalently bound to the glass, membrane, or gel surfaces. Microchips are used for serum proteomic studies in patients with cardiovascular diseases and cancer

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomic analysis by antibody microarrays
Description: Proteomic analysis by antibody microarrays can be used to identify novel biomarkers and to investigate various signaling pathways including protein phosphorylation and protein-protein interactions. Microchips are manufactured as a matrix of a number of immobilized antibodies covalently bound to the glass, membrane, or gel surfaces. Microchips are used for serum proteomic studies in patients with cardiovascular diseases and cancer

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomic analysis by antibody microarrays
Description: Proteomic analysis by antibody microarrays can be used to identify novel biomarkers and to investigate various signaling pathways including protein phosphorylation and protein-protein interactions. Microchips are manufactured as a matrix of a number of immobilized antibodies covalently bound to the glass, membrane, or gel surfaces. Microchips are used for serum proteomic studies in patients with cardiovascular diseases and cancer
Study: NCT05506007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5216
Description: During the cross-over \[Part A\], patients will be randomly assigned to receive one of the following treatment sequences:~* Sequence I. Single dose of DA-5216-R(Fasting) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8.~* Sequence II. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216-R(Fasting) on Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5216-R
Description: During the cross-over \[Part A\], patients will be randomly assigned to receive one of the following treatment sequences:~* Sequence I. Single dose of DA-5216-R(Fasting) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8.~* Sequence II. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216-R(Fasting) on Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5216
Description: During the cross-over \[Part B\], patients will be randomly assigned to receive one of the following treatment sequences:~* Sequence I. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216(Fed) on Day 8.~* Sequence II. Single dose of DA-5216(Fed) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5216
Description: During the cross-over \[Part B\], patients will be randomly assigned to receive one of the following treatment sequences:~* Sequence I. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216(Fed) on Day 8.~* Sequence II. Single dose of DA-5216(Fed) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8.
Study: NCT05010018

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based application connecting small food store owners and suppliers of healthier foods and beverages
Description: The primary intervention is a web-based app that connects small food store owners in low income Baltimore with suppliers of healthier foods and beverages. To reduce costs associated with small purchasing quantities by corner stores, and high delivery charges, the BUD app uses collective purchasing and shared delivery strategies. BUD will be implemented in four stages, where each stage promotes different food/beverage items and introduces new features. The app will be bundled with a small subsidy in stages 1-2 to encourage initial use, increase familiarity with the app and reduce risk. Trainings in the use of the app will take place at the beginning of each phase. BUD will use collective purchasing at stage 2 of implementation (BuddyUp!). The BuddyLift! feature will start in stage 3, enabling small store owners to deliver BuddyUp! deals to other stores for an additional discount. Participating stores and wholesalers will receive point of purchase materials to promote BUD products.
Study: NCT06196281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wooble board proprioceptive training
Description: this includes wooble board proprioceptive training twice a day for four weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wooble board proprioceptive training
Description: this includes wooble board proprioceptive training twice a day for four weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multi-station proprioceptive training
Description: this includes multi-station proprioceptive training twice a day for four weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multi-station proprioceptive training
Description: this includes multi-station proprioceptive training twice a day for four weeks
Study: NCT06432595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instability resistance training and Traditional resistance training
Description: The 20 intervention actions were divided into three levels (primary, intermediate, and advanced) for instability resistance training and traditional resistance training. Both groups performed training for 60 minutes three times a week. The Swiss ball, BOSU ball, and Wobble boards only provided an unstable surface environment for instability resistance training. The intensity/load was body weight for both training methods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instability resistance training and Traditional resistance training
Description: The 20 intervention actions were divided into three levels (primary, intermediate, and advanced) for instability resistance training and traditional resistance training. Both groups performed training for 60 minutes three times a week. The Swiss ball, BOSU ball, and Wobble boards only provided an unstable surface environment for instability resistance training. The intensity/load was body weight for both training methods.